BioLife Solutions Inc BLFS Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Apr 22, 2024 (filed on Apr 23, 2024)

Insider Name:

Aebersold Sarah

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-410

Price:

$16.50
Apr 18, 2024 (filed on Apr 23, 2024)

Insider Name:

Aebersold Sarah

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-348

Price:

$15.31
Apr 18, 2024 (filed on Apr 23, 2024)

Insider Name:

Foster Karen A.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-481

Price:

$15.31
Apr 18, 2024 (filed on Apr 23, 2024)

Insider Name:

Mathew Aby J.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-584

Price:

$15.31
Apr 18, 2024 (filed on Apr 23, 2024)

Insider Name:

Berard Todd

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-332

Price:

$15.31
Apr 18, 2024 (filed on Apr 23, 2024)

Insider Name:

Wichterman Troy

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-956

Price:

$15.31
Apr 15, 2024 (filed on Apr 18, 2024)

Insider Name:

Berard Todd

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-10,000

Price:

$15.67
Apr 01, 2024 (filed on Apr 03, 2024)

Insider Name:

Aebersold Sarah

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,000

Price:

$17.65
Mar 27, 2024 (filed on Mar 29, 2024)

Insider Name:

Mathew Aby J.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-454

Price:

$17.99
Mar 27, 2024 (filed on Mar 29, 2024)

Insider Name:

Berard Todd

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-515

Price:

$17.99

Filings by filing date

Apr 22, 2024 (filed on Apr 23, 2024)

Insider Name:

Aebersold Sarah

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-410

Price:

$16.50
Apr 18, 2024 (filed on Apr 23, 2024)

Insider Name:

Aebersold Sarah

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-348

Price:

$15.31
Apr 18, 2024 (filed on Apr 23, 2024)

Insider Name:

Foster Karen A.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-481

Price:

$15.31
Apr 18, 2024 (filed on Apr 23, 2024)

Insider Name:

Mathew Aby J.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-584

Price:

$15.31
Apr 18, 2024 (filed on Apr 23, 2024)

Insider Name:

Berard Todd

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-332

Price:

$15.31
Apr 18, 2024 (filed on Apr 23, 2024)

Insider Name:

Wichterman Troy

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-956

Price:

$15.31
Apr 15, 2024 (filed on Apr 18, 2024)

Insider Name:

Berard Todd

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-10,000

Price:

$15.67
Apr 01, 2024 (filed on Apr 03, 2024)

Insider Name:

Aebersold Sarah

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,000

Price:

$17.65
Mar 27, 2024 (filed on Mar 29, 2024)

Insider Name:

Mathew Aby J.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-454

Price:

$17.99
Mar 27, 2024 (filed on Mar 29, 2024)

Insider Name:

Berard Todd

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-515

Price:

$17.99

News

Biz Brief

Sector: Healthcare	Industry: Medical Equipment, Supplies & Distribution

See Regulatory Filings on SEC

Company Contact

Address:	SUITE 310, 3303 MONTE VILLA PARKWAY BOTHELL WA 98021
Tel:	1-425-4021400
Website:	https://www.biolifesolutions.com
IR:	See website

Key People

Roderick De Greef Chairman of the Board, Chief Executive Officer, President	Troy Wichterman Chief Financial Officer	Aby J. Mathew Executive Vice President, Chief Scientific Officer
Geraint Phillips Senior Vice President - Global Operations	Todd Berard Chief Marketing Officer	Sarah Aebersold Vice President - Global Human Resources
Karen A. Foster Chief Quality Officer	Garrie Richardson Chief Revenue Officer

Business Overview

BioLife Solutions, Inc. is a supplier of cell processing tools and services for the cell and gene therapy (CGT) and broader biopharma markets. Its expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage and distribution. Its biopreservation media products, HypoThermosol FRS and CryoStor Freeze Media, are formulated to mitigate preservation-induced, delayed-onset cell damage and death which result when cells and tissues are subjected to reduced temperatures. Its bioproduction tools portfolio includes human platelet lysates for cell expansion. It is a provider of biological and pharmaceutical storage and cold chain logistics. Its monitoring systems allow customers real time tracking of the storage temperatures of their materials throughout the logistics process. It operates about five storage facilities in the United States and one facility in the Netherlands.

Financial Overview

For the fiscal year ended 31 December 2023, BioLife Solutions Inc revenues decreased 11% to $143.3M. Net loss decreased 52% to $66.4M. Revenues reflect Product Revenue-Freezer and thaw segment decrease of 24% to $50.6M, Product Revenue-Cell processing segment decrease of 4% to $65.8M, United States segment decrease of 2% to $114.6M, Other Countries segment decrease of 11% to $5.7M.

Employees:	409 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$769.99M as of Dec 31, 2023
Annual revenue (TTM):	$143.27M as of Dec 31, 2023
EBITDA (TTM):	-$43.04M as of Dec 31, 2023
Net annual income (TTM):	-$66.43M as of Dec 31, 2023
Free cash flow (TTM):	-$23.74M as of Dec 31, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	45,300,000 as of Feb 22, 2024
Index Membership:	S&P 600 Small Cap
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization